



Calmark ships instruments to India for a method comparison study

Calmark Sweden AB announces today that they are sending 2 units with associated bilirubin test cassettes to the distributor r2 Diagnostics in India. The distributor plans to use the products for a method comparison.

Calmark, together with r2 Diagnostics, has been working for a long time for a registration of Calmark Neo – Bilirubin on the Indian market. r2 Diagnostics plans to carry out a method comparison at state-accredited laboratories in the country. The result of the method comparison will be submitted to the registration authority in India as a supplement to other submitted material.

"India is an important market for Calmark, even though the registration process is complicated. We hope that this moves the process forward," comments CEO Anna Söderlund.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.